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Abstract
The clinical pharmacokinetics, metabolism and renal excretion of articaine and its metabolite articainic acid 
have been investigated in man after epidural administration. ( db )-Articaine and its metabolite ( ±  )-articainic 
acid have different pharmacokinetic constants (P — 0*0079) except for lag-time (tiag; 0-06 min), first phase 
distribution of elimination (tja; 049 ±0-21 h), and elimination half life (tL; 2,19 ±0.98 h), which are all the 
same for both compounds. The total body clearance of articaine (103 ±57 L h ~ *) is 10 times higher than that 
of the metabolite articainic acid (10*7 ±  1-80 L h“ \  P ~  0-0079). With similar half-life (t^) values (2 h), the 
volumes of distribution (V^) are 10 times higher for the parent drug than for the metabolite ((329 ±212 L 
compared with 384 ±7-5 L, respectively; P =  0-0079). The difference between the areas under the curves for 
total plasma articainic acid and that formed in the plasma gives an indication of the percentage metabolism 
during epidural transfer (5-38 ±  1*51%). This percentage of metabolism corresponds to a mean epidural transfer 
time of 5 min. The main compound in the urine is articainic acid (64-2 ±  14-4%), followed by articainic acid 
glucuronide (134 ±4-97%) and the parent drug (145 ±0*77%). In total, 79-0 ±18-5% of the dose is recovered 
in the urine. The renal clearance of articaine is 22-5 ±13*9 mL m in~\ whereas that of articainic acid is 
119-6 ±30*1 mL min (P <0-0001), The apparent renal clearance of articainic acid glucuronide was 
25-4±12*0 mL min” 1. This value does not differ from that of the parent drug (P>0-8). Articainic acid 
glucuronide is not present in plasma, but has an apparent renal clearance of 25 mL min-1 .
These results suggest that articainic acid is glue uro ni dated by the tubular cells and then excreted.
Articaine (( ±  )-3-rc-propylamino-a-propionylamido-2-carbo~ 
methoxy-4-methylthiophen hydrochloride; MW 320-9, pKa 
7-8; CAS number 23964-57-0) is a local anaesthetic drug first 
clinically investigated in 1974 (Muschawek & Rippe! 1974; 
Kirch et al 1983). Only small differences were found when
li doc ai ne 2% or articaine 2 %, both with adrenaline 1 :2 0 0  000 , 
were used for epidural anaesthesia. The articaine had a slightly 
faster onset of action and probably less toxicity, especially to 
the heart and brain (Hendolin & Mattila 1974; Brinklov 1977; 
Moller & Covino 1993; Simon et al 1996),
Articaine 4% with adrenaline 1:200 000 is widely used in 
dentistry for infiltration and conduction anaesthesia. The very 
fast onset of the block, the excellent quality of the anaesthesia, 
the reduced toxicity and the shorter duration of action, owing 
to hydrolysis of the parent drug, are responsible for its wide 
utilization (Ferger & Marxkors 1973; van Oss et al 1989).
Epidural anaesthesia with 4% articaine with adrenaline 
1 :2 0 0  000 has several advantages over commonly used local 
anaesthetics such as ( ±  )-mepivacaine, lidocaine, (±)-prilo- 
caine and ( ±  )-bupivacaine: shorter time to onset (7 min); 
shorter sensory block (105 min) and motor block (65 min); 
more intense motor block (66% of patients completely par­
alysed); lower failure rate; no allergic reactions; lower toxicity; 
fewer post-operative complications (van Oss, personal obser­
vations).
( ±  )-Articaine is metabolized to ( ±  )-articainic acid (Fig.
Correspondence: T. B. Vree, Institute for Anaesthesiology, Aca­
demic Hospital Nijmegen Sint Radboud, Geert Grooteplein Zuid 10, 
6525 GA Nijmegen, The Netherlands.
1). It was noted in a group of 18 patients receiving 600 mg 
epidurally that the yield of articaine hydrolysis showed a 
bimodal character (van Oss, unpublished results); although the 
time-course of the experiment (3 h) was sufficient to follow the 
kinetics of the parent drug, it was too short to study the 
metabolite which requires a study over 30 h.
van Oss et al (1989) investigated the pharmacokinetics of 
( ±  )-articaine in five patients undergoing epidural local 
anaesthesia. Their main kinetic parameters were half-life, t ,^ 
percentage of the dose excreted, protein binding and renal 
clearance (van Oss et al 1989). Ongoing research on articaine 
by Simon et al (1996) showing regional metabolism of the drug 
suggested a more detailed re-investigation of the clinical 
pharmacokinetics of articaine after epidural administration.
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F ig . 1. Structural formulae of articaine and its metabolite articainic 
acid. ?
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The aim of this study was to re-investigate the clinical 
pharmacokinetics, metabolism and renal excretion of articaine 
and its metabolite articainic acid in man after epidural 
administration.
thereafter. Plasma and urine samples were kept at —20°C until 
analysis.
Materials and Methods
Drugs
Articaine and articainic acid were a gift of Hoechst Pharma 
(Amsterdam, The Netherlands).
Patients
Five patients (ASA I-II, classification according to the Amer­
ican Society of Anesthesiologists) undergoing elective surgery 
gave their informed consent to participate in this study, which 
was approved by the hospital Ethics Committee. The demo­
graphic data of the patients are summarized in Table 1. Pre- 
medication was with lorazepam, 2-5 mg, given orally the 
evening before surgery and repeated 2 h before surgery. An 
epidural needle was placed at the site through which a catheter 
was inserted and passed 4 cm cranially. For this procedure
1 -8 mL articaine 4% with adrenaline 1:200 000 was admi­
nistered subcutaneously before the puncture.
Induction of anaesthesia consisted of atropine 3-5 mg k g ~ \ 
fentanyl 1-5 mg kg-1 , thiopental 0-10 mg kg-1 , etomidate 
0-2 mg k g ~ l, and vecuronium 0-1 mg kg“ 1* All patients were 
endotracheally intubated and artificially ventilated to an end- 
tidal C 0 2 concentration of 4-5-5%. A central venous catheter 
was placed in the right internal jugular vein and an arterial 
catheter in a radial artery. A urinary catheter was inserted. 
Anaesthesia was maintained with a mixture of 60% nitrous 
oxide in oxygen and additional doses of fentanyl and vecur­
onium were administered as needed. Occasionally, dehy- 
drobenzperidol, midazolam, flue I oxacillin, furosemide or 
heparin was administered as needed.
Articaine (Ultracain, Hoechst; 4% solution» 15 mL =  
600 mg (2-112 mM)) with adrenaline 1 :200 000 was admi­
nistered during the operation via the epidural catheter.
Sampling
Blood samples were taken just before administration, at the 
end of administration (0), and 1, 2-5, 5, 10, 15, 20, 30, 40 and 
50 min and 1, 1-5, 2, 3, 4, 5, 6 , 7, 8 and 12 h thereafter in glass 
tubes containing 1 mg ecothiopate to prevent esterase hydro­
lysis. Urine samples were collected at 0*5, 1, 2, 3, 4, 5, 6, 7, 8, 
12, 16, 20, 24, 32 and 36 h, after administration. The samples 
were kept at 4°C during surgery and centrifuged immediately
Drug analysis
( ±  )-Articaine and its (=L) metabolite were determined by 
high-performance liquid chromatography as described else­
where (Vree et al 1988). In short, the separation was performed, 
on a 250 x 4 6 m m  Spherisorb 5 ODS column; the mobile 
phase was a 4 :6  (v/v) mixture of (4 g H 3PO 4,0-6 g TMACl in
1 L water) and acetonitrile at a flow rate of 1*5 mL min“ *, UV 
detection was achieved at 275 nm. Plasma (0*3 mL) was 
deproteinized with acetonitrile (0-3 mL), vortex mixed and 
centrifuged at 3000 g; 50 ¿¿L was injected on to the column.
The inter- and intra-day coefficients of variance for articaine 
and articainic acid were less than 5%.
Deglucuronidation. Urine (10 fiL) was incubated with ß- 
glucuronidase (10 /¿L; 10 000 units mL“ 1; from Escherichia 
coli Type VII (Sigma, St Louis, USA) and phosphate buffer 
(pH 6 *8; 100 juL). Reaction time was 16 h at 37°C.
Plasma (100 ¡xL) was incubated with glucuronidase 
(100 fih\ 10 000 units m L ~ J; from Escherichia coli Type VII 
(Sigma, St Louis, USA) and phosphate buffer (pH 6 -8 ; 
100 juL). Reaction time was 16 h at 37°C.
Data analysis
Pharmacokinetic parameters were calculated from the fitted 
plasma concentration-time curve (r2 > 0-98) according to a 2- 
compartment model using the MW/Pharm computer package 
(Mediware, Groningen, The Netherlands; Proost & Meyer 
1992). The elimination half-life (t^ ) values were calculated 
From ln2//?, where ß is calculated by log-linear regression 
analysis of the terminal log-linear phase. The area under the 
plasma concentration-time curve, AUC0-oo> was calculated 
using the linear trapezoidal rule with extrapolation of t to 00 
using Ct/ß , with Ct being the last measured concentration.
Total body clearance (CL) was calculated from CL =  
dose/AUCo-co. Vd, the volume of distribution in the central 
compartment, was calculated from Vd =  dose/CQ. Vss, the 
volume of distribution at steady-state, was calculated from 
Vss =  dose x AUMCo-co/AUCo-co2* where AUMC0_oo is the 
area under the moment curve from zero to t =  00, The volumes 
of distribution, Vß> were calculated from V^ =  CL/Cß> The 
mean residence time (MRT) after extravascular administration 
was calculated from MRT =  AUMCo-co/AUCo_co +  l /k a 4- to- 
The mean epidural transfer time (METT) was calculated from 
METT =  AUCt =  AUC0e ~ kt, where AUCt is the AUC for 
plasma-formed articainic acid and AUC0 is the AUC for total
Table 1. Demographic data of the patients.
Gender Age
(years)
Height
(cm)
Body weight 
(kg)
Surgery
1 F 49 165 65 Kidney artery stenosis
2 F 42 157 62 Thorax reconstruction
3 M 66 175 67 Femoro-popliteal bypass
4 M 76 177 80 Amputation of rectum
5 F 71 166 82 Diaphragmatic hernia repair
Mean (± s .d .) 60-8 ±  14-6 168-0 ±8-1 71-2 ± 9 -1
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articainic acid. The renai clearance of articaine and articainic 
acid were calculated from mg excreted/AUC (mg L ~ 1 h). The 
renal clearance of articainic acid glucuronide was calculated 
from [mg excreted acid H- gluc/AUCacjd]-ClR,add* The percent­
age excreted was calculated from mmolurîne/mmoldose x 
100%.
Analysis of variance was performed according to standard 
procedures. The level of significance was set at P =  0-05.
100*3
R esu lts
Fig. 2 shows the plasma concentration-time curves and renal 
excretion rate-time profiles of articaine and its metabolite 
articainic acid in one patient after epidural administration of 
articaine (600 mg).
Fig. 3 shows the mean plasma concentration-time curves of 
articaine and its metabolite articainic acid in the five patients. 
In the first blood sample (t == 0), the plasma concentration of 
the metabolite articainic acid (2-06 ±0*54 mg mL“ 1) is 
already higher than that of the parent drug (0-60 ±  0*27 mL-  \
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Fig . 2. Plasma concentration-time curves and renal excretion rate­
time profiles of articaine, its metabolite articainic acid (COOH) and the 
corresponding glucuronide conjugate (COOHgluc) in one patient after 
epidural administration of 600 mg articaine.
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F ig. 3. Mean plasma concentration-time curves of articaine and its 
metabolite articainic acid in the five patients. The terminal half-lives of 
elimination run parallel.
Table 2, Mean plasma concentrations of articaine and articainic acid 
(mg L " 1; mean ±  s.d.) after epidural administration of 600 mg 
(2-112 mM) articaine.
Time Articaine Articainic acid
min h Total Plasma-formed
0 0 0*60 ± 0-27 2*06 ±0*54 0*00 ±0-00
1 0*017 3*08 ±2*45 2*46 ±  1 *03 0*46 ±0-58
2*5 0*042 4*54 ±2*37 3*18 ±2*03 1*20 ±1-57
5 0-083 4*79 ±2-31 3*78 ±3*12 1 *86 zb 2-71
10 0-166 5*14±2-35 4*50 ±3*43 2-68 ±3*00
15 0*25 5*04 ±2*37 5*26 ±3*52 3*55 ±3*11
20 0*33 4*48 ±  1 -54 6-36 ± 4-44 4-77 ±4*04
30 0*50 4*37 ±  249 7 *62 ±4*96 6*19 ±4-63
40 0*66 3*96 ±2*27 8*74 ±3-37 7-46 ±3*08
50 0*83 3-39±2*12 9*66 ±3*50 8*64±3*53
60 1-0 2*88 ±1*86 ll*4±3*77 10-4± 3 ’57
90 1*5 1*52 ±0*83 11 *2 ± 2-50 10*5 ±  2-38
120 2-0 0*83 ±0*44 8*90 ±0*75 8*40 ±0*82
180 3*0 0-44 ±0*25 7*32 ±1*45 7-14 zb 1 *53
240 4*0 0*29 ±0*18 5 *40 ±1*94 5*37 ±1*93
300 5*0 0*15 ±0*07 4* 12 ±1*66 4-12 db 1 -66
360 6*0 0*089 ±0*051 2*92 ±1*48 2-92 ±1*48
420 7-0 0-061 ±0*041 2*31 ±1*34 2-31 ±1*34
480 8*0 0*047 ±0*018 1 *66 ±  1 *02 1 -66 zb 1 *02
720 12-0 0*014±0*013 0*54 ±0*38 0-54 ±0*38
P =  0*0079; Table 2). The terminal half-lives of elimination 
run parallel.
Fig. 4 shows the mean plasma concentration-time curves of 
articaine and its metabolite during the first hour after epidural 
administration. In the first plasma sample, the concentration of 
the metabolite is higher than that of the parent drug.
Table 3 summarizes the mean (± s.d .) pharmacokinetic 
constants derived from the plasma concentration-time curves 
in each volunteer. Articaine and articainic acid have different
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Fig . 4. Mean plasma concentration-time curves of articaine and its 
metabolite articainic acid during the first hour after epidural adminis­
tration. In the first plasma sample the concentration of the metabolite is 
higher than that of the parent drug.
pharmacokinetic constants (P =  0*0079) except for tiag, tL and 
%•
Differences in the kinetics of the parent drug can be 
explained by differences in the rate of release from the epidural 
space, as reflected by the absorption half life (t£abS), which 
varies 10-fold from 54 s (0-015 h) to 9 min (0-152 h; mean 
0-063 ±0-052 h =  3-8 min) (Table 3).
The rapid absorption showed short times for maximum 
plasma concentration (tmax) of 12 min (0-203 ±0*101 h) and 
relatively high maximum plasma concentration (Cmax) of 
5-30 ±2-02 mg m L ^ 1. Thereafter, the elimination of articaine 
can be described by a two-compartment model with a t¿a of 
30 min (0-49 ±  0-21 h) and a Vd of 99*0 ±41*7 L followed by 
a l\ß of 2*19±0*98 h and a Vp of 329±212  L. The overall 
MRT is 1-64±0*49 h and the Vss is 154±72*6 L.
The total body clearance of articaine (103 ± 5 7  L h*"1) is 10 
times greater than that of articainic acid (10*7 ±  1*80 L h “ 1; 
P =  0-0079). With identical values, the volumes of dis­
tribution are also 10 times higher for the parent drug than for 
the metabolite (ƒ>= 0*0079).
Fig. 5 shows the mean plasma concentration-time curves of 
total articainic acid and articainic acid formed in plasma. The 
difference between the plasma ÁUC of total articainic acid and 
that formed in plasma gives an indication of the percentage 
metabolism during epidural transfer (5*38 ±  1-51%). This 
percentage metabolism corresponds with a mean epidural 
transfer time of 5 min.
Table 3. Pharmacokinetic parameters of articaine and articainic acid (mean ±  s.d.) after epidural administration of 600 mg 
(2*112 mM) articaine.
Parameter Articaine Articainic
acid
p* Articainic acid glucuronide
Maximum plasma
concentration (mg mL"’ 1) 
Time for maximum plasma 
concentration (h) 
Lag-time (h)
Absorption half-life (h)
5*30 ±2-02
0*203 ±0*101 
0*001 ±0*0 
0*063 ±0*052
13*81 ± 3-23
1*31 ±0*62 
0*001 ±0*0 
0*65 ±0*35
0*0079
0-0079
1*0000
0*0079
4« (h) 0 4 9  ±0*21 0-90 ±0*61 0-1508
Elimination half-life (h)
Mean residence time (h)
Area under the plasma 
concentration time curve 
(mg L “ 1 h)
</jmol L h)
Total body clearance (L h “ 1) 
Volume of distribution in 
the central compartment (L) 
Volume of distribution at 
steady-state (L)
Volume of distribution (L)
2*19 ±0*98 
1*64 ±  0*49
7*42 ±3-32 
26* 14 ±  11*71 
103 ±57*0
99*0 ± 41  *7
154 ±72*6 
329 ±212
2-54 ±0*64 
3*62± 1*06
51*74 ± 8 -99  
191 ± 3 3 4  
10*70± 1*80
19*35 ±9*89
28*24 ±5*96 
3 8 * 3 6 ± 7 4 6
0*8413
0*0079
0*0079
0*0079
0*0079
0-0079
0*0079
0*0079
Renal excretion 
% Dose excreted 
Total % excreted
145 ±0*77 64*2 ±14*4 <0*0001 1 3 4  ±4*97 
79-0 ±18*5
Renal clearance 
mL m in“ 1 
L  h " 1
22*5 ±13*9 
1*36±0*84
119-6 ±  30-1 
7*20 ±1*82
<0*0001 
<  0*0001
25 *4 ±12*0 
1*52 ±0*71 ,P>0*8 with parent
Epidural metabolism 
% dose 5*38 ±1-51
’•'Unpaired non-parametric test, Mann-Whitney two-sample test.
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Time (h)
F ig . 5. Mean plasma concentration-time curves of total articainic 
acid ( • )  and that formed in plasma (□ ). The difference in AUC 
reflects metabolism during epidural transfer of the parent drug.
administration are highly patient dependent (Koopman- 
Kimenai et al 1991, 1995; van Oss et al 1989).
Epidural metabolism
In the first blood sample (t =  0), the plasma concentration of 
the metabolite is already higher than that of the parent drug 
(Table 2). This means that hydrolysis must have taken place 
during the epidural transfer. When the C0 of articainic acid is 
considered as a fixed amount of drug entering the general 
circulation, this amount is eliminated with the intrinsic half-life 
of 1 h, as if the compound was administered intravenously 
(van Oss et al 1988a, b). When these extrapolated plasma 
concentrations were subtracted from the total plasma con­
centrations of articainic acid, the plasma concentration-time 
curve of articainic acid formed from hydrolysis by plasma 
esterase activity remains (Fig. 5). A similar observation was 
made with articaine after a 30-min disposition time in an 
exsanguinated arm during intravenous regional anaesthesia 
(Simon et aí 1996).
The difference between the ‘total and corrected' plasma 
AUCs of articainic acid gives an indication of the percentage 
metabolism during the epidural transfer (5%). This percentage 
metabolism corresponds to a mean epidural transfer time of
5 min.
The main compound excreted in the urine is the metabolite, 
which is also partly glucuronidated. Only 1*5% of articaine is 
excreted unchanged.
The main compound in the urine is articainic acid 
(64*2 dt 14-4%), followed by articainic acid glucuronide 
(13-4 ±4*97%) and the parent drug (1-45 db 0-77%). In total 
79-0 ±18-5% of the dose is recovered from the urine. The 
renal clearance of articaine is 22-5 ±  13-9 mL min- 1, whereas 
that of its metabolite articainic acid is 119-6 ±30-14 mL 
min~ 1 (P < 0*0001). The apparent renal clearance of articainic 
acid glucuronide was 25*44 ±  11-97 mL m in "1. This value is 
not different from that of the parent drug (P > 0*8).
Discussion
The metabolic fate of articaine and its nearest structural ana- 
ue, prilocaine, are different. Prilocaine is mainly hydrolysed 
to £?-toluidine and N-propylalanine (Akerman et al 1966). The
2-carbomethoxy group in articaine prevents this hydrolysis; 
instead, this group is hydrolysed by esterase activity to the 2 - 
carboxy group and the drug is largely (40-80%) excreted in the 
urine as the metabolite articainic acid. Only a small percentage 
(5-17%) is excreted as the glucuronide of articainic acid. This 
ester-type glucuronide is stable in urine between pH 5 and pH 
7 (van Oss et al 1989, 1988a, b).
When articainic acid was administered as the study com­
pound, 78% was excreted unchanged and 22% as glucuronide. 
In these circumstances» articainic acid showed an intrinsic t^  of 
elimination of 1 h (van Oss et al 1988a, b). This implies that all 
articainic acid formed after epidural absorption and hydrolysis 
is excreted immediately and that variations in the recovery of 
the articainic acid metabolite must therefore reflect patient- 
dependent variation in the release of articaine from the epi­
dural space. The pharmacokinetics of drugs after epidural
Renal clearance and glucuronidation 
The apparent renal clearance of articainic acid equals that of 
creatinine. When this renal clearance is corrected for protein 
binding of 77% (van Oss et al 1989), the metabolite is excreted 
by glomerular filtration and active tubular secretion (van Oss et 
al 1989, 1988a, b).
The apparent renal clearance values of articainic acid glu­
curonide and of articaine are similar. Both clearances differ 
significantly from that of articainic acid (P <  0-0001). Arti­
caine, as a basic compound, is subject to passive tubular re­
absorption, and renal clearance will be dependent on urine pH 
and flow.
Articainic acid glucuronide is not present in plasma, but has 
an apparent renal clearance of 25 mL min-1 . There are two 
possible explanations for this: either articainic acid enters the 
renal tubule where it is partly glucuronidated and thereafter 
excreted, or articaine is strongly reabsorbed by the kidney 
tubule, is hydrolysed in the tubule cell, then glucuronidated, 
and thereafter excreted. The first possibility seems less likely, 
because a compound that is actively excreted is unlikely to be 
conjugated at the same time. The second possibility seems 
more likely. After tubular re-absorption, the compound is 
hydrolysed by tissue esterases, glucuronidated and thereafter 
excreted. A similar renal conjugation process has been 
described for probenecid (Vree et al 1992), indomethacin 
(Vree et al 1994) and for the N-glucuronidation of sulphadi- 
methoxine (Vree et al 1990a), sulphaphenazole (Vree et al 
1990b) and furosemide (Vree et al 1995a, b). When articainic 
acid was administered intravenously to a human subject, 
however (van Oss et al 1988a, b), articainic acid glucuronide 
was present in the urine (22% dose). Thus the first possibility 
must, against all the odds, describe the actual situation.
a
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Clinical implications
During epidural disposition, approximately 5% of the dose is 
lost owing to hydrolysis. This small and inevitable loss has no 
clinical implications. Measuring parent drug and metabolite 
always generates the question about whether the metabolite 
contributes to the overall local anaesthetic effect, especially 
when the metabolite concentrations are higher than those of the 
parent drug.
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